PeterO'DwyerMD

Oncology • Philadelphia, PA

Gastrointestinal Cancer

Professor, Medicine, Perelman School of Medicine

Join to view full profile

Dr. O'Dwyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. O'Dwyer's full profile

Already have an account?

Office
3400 Spruce St
# 15
Philadelphia, PA 19104
Phone+1 215-662-3914

Fax+1 215-615-3380

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1981 - 1982
Greater Baltimore Medical CenterResidency, Internal Medicine, 1979 - 1981
Yale-New Haven Medical CenterResidency, Pediatrics, 1977 - 1979
University of Dublin Trinity CollegeClass of 1975

Certifications & Licensure

PA State Medical License 1986 - 2024
MD State Medical License 1980 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors Start of enrollment: 1997 Apr 01
Completed
Phase 1
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Start of enrollment: 2008 Nov 07
Completed
Phase 2
Metastatic Colorectal Cancer: Treatment Response With Dynamic Contrast MRI Start of enrollment: 2008 Apr 01
Terminated
GI-4000 With Adoptive Transfer in Pancreatic Cancer Start of enrollment: 2008 Jan 01
Withdrawn
Phase 1
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Start of enrollment: 2010 Sep 17
Completed
Phase 2
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 1
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
DCE-MRI PET Bevacizumab Study in Rectal Cancer Start of enrollment: 2011 Aug 01
Withdrawn
Phase 2
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer Start of enrollment: 2012 Mar 01
Completed
Phase 2
A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma Start of enrollment: 2013 Apr 01
Completed
Phase 2
A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 1
Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases Start of enrollment: 2015 Sep 10
Enrolling by invitation
A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer Start of enrollment: 2017 Apr 10
Completed
Phase 2
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Start of enrollment: 2017 Sep 28
Terminated
Phase 1
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer Start of enrollment: 2020 Jul 29
Terminated
Early Phase 1
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors Start of enrollment: 2019 Feb 15
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

27 citations
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of NUT carcinoma and other cancers: results of a phase I/II open-label, ...
Sophie Cousin, Jean-Yves Blay, Irene Braña Garcia, Johann S. de Bono, Christophe Le Tourneau
International Journal of Cancer. 2021-11-01
1 citations
THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma.
Phyllis A. Gimotty, Jacob Till, Shirsa Udgata, Naomi Takenaka, Stephanie S. Yee
Oncotarget. 2021-10-26
6 citations
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: ...
Komal Jhaveri, X. V. Wang, Vicky Makker, Shiuh-Wen Luoh, Edith P. Mitchell
Annals of Oncology. 2021-06-04

Journal Articles

Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy
Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimoseg..., Cell, 2014
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ., Clin Cancer Res, 2013
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Köhne CH, Tejpar S, Gladkov O, Davidenko I, Salazar R, Vladimirova L, Cheporov S, Burdaeva O, Rive..., Clin Cancer Res, 2013
Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy.
Selvakumaran M, Amaravadi RK, Vasilevskaya IA, O'Dwyer PJ, Clin Cancer Res, 2013
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Mess..., Lancet Oncology, 2012
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).
Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, Courtney R, O'Dwyer PJ., Br J Cancer, 2012
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH., Science, 2011
Inhibition of mutated, activated BRAF in metastatic melanoma.
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB, New Engl J Med, 2010
Join now to see all

Lectures

Basket Trials in Colorectal Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018

Press Mentions

Head and Neck Cancer Researchers Demonstrate the Capability of a Deep Learning Algorithm in the Post-Surgery Setting to Assess the Stage of Disease More Accurately Using Standard CT ScansOctober 21st, 2022
Clinical Outcomes in Early Breast Cancer with a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical TrialMarch 1st, 2020
Association of Circulating Tumor Cells with Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialDecember 1st, 2019
Join now to see all